Remicade (infliximab) - J&J
Humira (adalimumab) - AbbVie
Tremfya (guselkumab) - J&J
tofacitinib - Generic mfg.
Stelara (ustekinumab) - J&J
Rinvoq (upadacitinib) - AbbVie
Entyvio (vedolizumab) - Takeda
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature. (PubMed, World J Gastrointest Pharmacol Ther) - Sep 9, 2026 - "In multi-refractory IBD, add-on ACT may convert partial response into deep remission, averting surgery in selected patients." 
Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Ulcerative Colitis
http://www.ncbi.nlm.nih.gov/pubmed/42707483
 
Daniel Jun Funatsu Brambilla; Eduardo Brambilla; Jonathan Soldera; Leticia Nodari Carobin; Maria Antonia Selbach Pertile
 
Sep 9, 2026
 
Prev Next